Here are the latest G-BA decisions from the G-BA meeting held on 3 July 2025 on the early benefit assessments of Casgevy, Palforzia, and Tagrisso.
A complete database of all previous G-BA resolutions is in my membership.
- Casgevy (exagamglogen autotemcel):
- beta-thalassemia, transfusion-dependent, ≥ 12 years, no HLA-compatible related stem cell donation available – Orphan drug, Indication of not-quantifiable additional benefit
- sickle cell disease with recurrent vaso-occlusive crises; ≥ 12 years; no HLA-compatible related stem cell donation available – Orphan drug, Hint of not-quantifiable additional benefit
- Palforzia (peanut protein as defatted powder from Arachis hypogaea L., semen); new indication: peanut allergy, ≥ 1 to < 4 years – Hint of not-quantifiable additional benefit
- Tagrisso (osimertinib); new indication: non-small cell lung cancer, EGFR mutations, after platinum-based chemoradiotherapy – Additional benefit not proven in either subgroup
Follow me on Instagram to never miss the latest G-BA decisions: